Close Menu
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
What's Hot

Oil prices fall as investors ponder developments in the Middle East

June 23, 2026

Oracle cuts 21,000 positions in the past year as tech giant cuts AI headcount

June 23, 2026

CNBC Daily Open: US waives sanctions on Iran. mega cap rotation

June 23, 2026
Facebook X (Twitter) Instagram
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Facebook X (Twitter) Instagram
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Home » Omada Health begins prescribing obesity treatment drugs such as GLP-1
World

Omada Health begins prescribing obesity treatment drugs such as GLP-1

Editor-In-ChiefBy Editor-In-ChiefNovember 7, 2025No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email


The Omada Health logo will appear on your smartphone screen.

Sopa Images | Light Rocket | Getty Images

virtual care company Omada Health announced Thursday that it will begin prescribing GLP-1 and other obesity drugs and helping patients manage them.

Omada plans to expand its weight management program offerings as its membership grows to more than 800,000.

The announcement comes as the digital health company expands its presence in the blockbuster market for GLP-1 to treat obesity, diabetes and other chronic diseases. Some analysts say this market could be worth about $100 billion by the end of 2010. Several digital health companies are offering GLP-1 prescriptions as well, and the manufacturers of these drugs, Eli Lilly and Novo Nordisk, are taking steps to make treatments more accessible while developing new treatments for patients.

“This announcement is in response to our belief that access to GLP-1 will increase significantly over time,” Omada co-founder and CEO Sean Duffy said in an interview. He said Omada recognizes that the market will expand beyond GLP-1 injections to tablets and other “next generation” treatments that work in different ways, emphasizing the need to help patients manage their medications.

Programs from companies like Omada aim to support lifestyle and behavioral changes for patients taking these drugs, offering resources such as nutritional guidance, education, and a team of health coaches and exercise experts to help people take their medications for longer. However, Omada now utilizes licensed healthcare professionals trained in obesity treatment to prescribe medications and assist patients in managing their medications.

This new service will allow the company to support patients from the time they receive their prescription to the time they begin taking GLP-1. This type of support is critical because GLP-1 injections can be complex for patients to use properly and are often associated with gastrointestinal side effects that force some to discontinue treatment.

“If you need to increase or decrease your dose, change your medication, whatever. We can support you through this experience,” Duffy said.

Omada, which partners with national and local health plans and employers, also said the new service is an add-on to help customers better support the health needs of their workers while controlling costs and improving bariatric treatment outcomes.

Also on Thursday, Omada Health announced its second quarterly results since its initial public offering in June.

Founded in 2011, the company offers virtual care programs to support patients with chronic conditions such as prediabetes, diabetes, and hypertension. Omada describes its approach as a “visit-to-visit care model” that complements the broader healthcare ecosystem.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor-In-Chief
  • Website

Related Posts

Oil prices fall as investors ponder developments in the Middle East

June 23, 2026

CNBC Daily Open: US waives sanctions on Iran. mega cap rotation

June 23, 2026

Growth of China’s 618 Shopping Festival slows sharply as consumer spending remains sluggish

June 23, 2026
Add A Comment

Comments are closed.

News

What to know about Tuesday’s primary elections in Maryland, Utah, New York | Elections News

By Editor-In-ChiefJune 23, 2026

Less than five months remain before the United States holds its midterm elections, which are…

U.S. judge blocks Trump administration subpoena of Minnesota officials | Court News

June 22, 2026

Left-leaning? What you need to know about New York Democratic primaries | 2026 US Midterm Election News

June 22, 2026
Top Trending

OpenAI launches new initiative to help find and patch open source bugs

By Editor-In-ChiefJune 22, 2026

OpenAI on Monday announced a new initiative designed to help the open…

Shortlist: Employers will make big tech layoffs in 2026 due to AI.

By Editor-In-ChiefJune 22, 2026

Oracle on Monday said it has cut its workforce by 21,000 employees…

Nvidia wants to reduce data center water usage, but that’s not the same as solving AI’s water problem

By Editor-In-ChiefJune 22, 2026

Nvidia just announced a hot water cooling system that can significantly reduce…

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Welcome to WhistleBuzz.com (“we,” “our,” or “us”). Your privacy is important to us. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our website https://whistlebuzz.com/ (the “Site”). Please read this policy carefully to understand our views and practices regarding your personal data and how we will treat it.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Facebook X (Twitter) Instagram Pinterest
  • Home
  • Advertise With Us
  • Contact US
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • About US
© 2026 whistlebuzz. Designed by whistlebuzz.

Type above and press Enter to search. Press Esc to cancel.